KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to 6.02%.

  • Biomarin Pharmaceutical's EBIT Margin fell 212900.0% to 6.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.89%, marking a year-over-year increase of 71800.0%. This contributed to the annual value of 16.97% for FY2024, which is 92900.0% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its EBIT Margin stood at 6.02% for Q3 2025, which was down 212900.0% from 33.55% recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's EBIT Margin ranged from a high of 33.55% in Q2 2025 and a low of 14.65% during Q4 2021
  • Moreover, its 5-year median value for EBIT Margin was 7.33% (2022), whereas its average is 8.77%.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's EBIT Margin surged by 212800bps in 2022, and later crashed by -212900bps in 2025.
  • Biomarin Pharmaceutical's EBIT Margin (Quarter) stood at 14.65% in 2021, then soared by 83bps to 2.43% in 2022, then soared by 273bps to 4.22% in 2023, then skyrocketed by 412bps to 21.6% in 2024, then plummeted by -128bps to 6.02% in 2025.
  • Its last three reported values are 6.02% in Q3 2025, 33.55% for Q2 2025, and 30.05% during Q1 2025.